Form 8-K - Current report:
SEC Accession No. 0001193125-25-029814
Filing Date
2025-02-20
Accepted
2025-02-19 21:49:44
Documents
15
Period of Report
2025-02-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d869543d8k.htm   iXBRL 8-K 26809
2 EX-99.1 d869543dex991.htm EX-99.1 27983
  Complete submission text file 0001193125-25-029814.txt   221990

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dvax-20250219.xsd EX-101.SCH 3877
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dvax-20250219_def.xml EX-101.DEF 13673
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20250219_lab.xml EX-101.LAB 22622
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20250219_pre.xml EX-101.PRE 14641
18 EXTRACTED XBRL INSTANCE DOCUMENT d869543d8k_htm.xml XML 5485
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 25643043
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)